FASTEST GROWING OTC ALLERGY BRAND1
coh-inline-element button-primary animation-off coh-style-secondary-button remove-border-bottom COMPARE VS INS
PRN NASAL SYMPTOM RELIEF THAT STARTS WORKING IN
Astepro® Allergy is different than INS sprays
- Starts working in 30 minutes2,9,† while INS sprays take hours to start to provide relief and can take between 3 and 14 days to reach maximum efficacy levels3-8,‡
- Starts working in 30 minutes2,9,† while INS sprays take hours to start to provide relief and can take between 3 and 14 days to reach maximum efficacy levels3-8,‡
- Flexibility to dose PRN, once or twice a day, versus the leading allergy spray products that recommend daily dosing schedules that may not match patient usage behavior10,13,14,§
- Flexibility to dose PRN, once or twice a day, versus the leading allergy spray products that recommend daily dosing schedules that may not match patient usage behavior10,13,14,§
See how Astepro® compares with INS
OTC ASTEPRO® OFFERS ADVANTAGES VERSUS RX AZELASTINE 0.10%
OTC ASTEPRO® OFFERS ADVANTAGES VERSUS RX AZELASTINE 0.10%
MAXIMUM STRENGTH
Azelastine HCl (0.15%) has a 50% higher
concentration per spray than Rx azelastine 0.10%10,17-19
IMPROVED TASTE
Includes a sweetener to improve its taste
profile versus Rx azelastine 0.10%10,17,20
LONGER DURATION
Offers nasal symptom relief for up to
24 hours, while Rx azelastine 0.10% only
has a 12-hour indication10,19
Powerful, steroid-free nasal symptom relief for up to 24 hours10
- Relief of indoor and outdoor allergies of nasal congestion, runny nose, itchy nose, and sneezing, without steroids or an additional decongestant10
- The same as prescription Astepro® Allergy (azelastine HCl 205.5 mcg) nasal spray10,17-19
FDA approved for children age 6+
- Steroid-free relief of nasal allergy symptoms including congestion10
- Dosing as needed10,||
- Dosing as needed10,||
- Does not have a label warning regarding pediatric growth suppression10
INS, intranasal steroid.
*Compared with steroid allergy sprays on day 1.
†On day 1.
‡INS onset based on various product information; time to maximum efficacy depends on the INS brand.
§In a survey of allergy patients that included nasal spray users (n=732), 42% of patients said they administer their INS “some days and not others.”13
||Up to twice daily.
REFERENCES:
1. Data on file. Bayer. Fastest growing. 2. Hsu S-N, Stevens DA, Sajjad F, Salapatek AM. Onset of action of azelastine HCl nasal spray 0.15% evaluated in an environmental exposure chamber. Poster presented at: ACAAI Annual Scientific Meeting; November 10-14, 2022; Louisville, KY. 3. Flonase® website. Accessed March 18, 2024. https://www.flonase.com/faqs/ 4. Flonase®. Prescribing Information. GlaxoSmithKline; 2019. 5. Haleon Health Partner website. Accessed March 18, 2024. https://www.haleonhealthpartner.com/en-us/respiratory-health/brands/flonase-products/flonase/dosing-administration-flonase-allergy-relief/ 6. Nasacort® website. Accessed March 18, 2024. https://www.nasacort.com/allergy-nasal-spray 7. Nasacort® AQ. Prescribing information. Sanofi-aventis U.S. LLC; 2008. 8. Budesonide Nasal Spray. Prescribing information. Apotex Inc.; 2011. 9. Shah S, Berger W, Lumry W, La Force C, Wheeler W, Sacks H. Efficacy and safety of azelastine 0.15% nasal spray and azelastine 0.10% nasal spray in patients with seasonal allergic rhinitis. Allergy Asthma Proc. 2009;30(6):628-633. doi:10.2500/aap.2009.30.3296 10. NDA 213872. 11. FDA approves a nasal antihistamine for nonprescription use. Approval is a first-in-class and was enabled by the prescription to nonprescription switch process. News release. FDA; June 17, 2021. Accessed March 18, 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-nasal-antihistamine-nonprescription-use 12. Data on file. Bayer. IRI data. Only OTC AH. 13. Data on file. Bayer. Habits and practices. 14. Ortiz G, Knudtson M. Counseling patients on the use of intransal steroids in allergic rhinitis management. Consultant. 2017;57(6):328-334. 15. Flonase® Drug Facts Label. NDA205434. 16. Nasacort® Drug Facts Label. NDA020468. 17. Astepro®. Prescribing information. Meda Pharmaceuticals Inc; 2018. 18. US Department of Health and Human Services. Pediatric Postmarketing Pharmacovigilance and Drug Utilization Review. November 3, 2016. Accessed February 28, 2024. 19. Astelin. Prescribing information. Meda Pharmaceuticals Inc; 2014. 20. van Bavel J, Howland WC, Amar NJ, Wheeler W, Sacks H. Efficacy and safety of azelastine 0.15% nasal spray administered once daily in subjects with seasonal allergic rhinitis. Allergy Asthma Proc. 2009;30(5):512-518. doi:10.2500/aap.2009.30.3284